Search
Search
Eyewire News: The Podcast
09.02.26
The FDA accepts Nicox’s NDA for an investigational glaucoma drop; Bausch + Lomb provides updates on two key investigational therapies for dry eye and ocular surface pain; and Ocugen doses the first patient in a global phase 3 trial of an investigational gene therapy for geographic atrophy (GA). Learn more about your ad choices. Visit megaphone.fm/adchoices
View full description +
Subscribe
07.22.26
PRIMA Retinal Implant Launched in EUShow More
